Carillon Mitral Contour System for Treatment of Exercise Induced Functional Mitral Regurgitation (EXERCISE FMR)

The EXERCISE FMR Trial: An Initial Evaluation of the Carillon Mitral Contour System for Treatment of Exercise Induced Functional Mitral Regurgitation

Evaluate the hemodynamic and anatomical effect of the commercially available CMCS system within its current indication on a subset of patients with exercise induced mitral regurgitation. This will be primarily evaluated by standard of care exercise testing and echocardiography. The purpose is to evaluate HFrEF CHF patients that may have mild to moderate-severe MR at rest but aggravated upon activity.

Study Overview

• Status: Withdrawn
• Conditions: Mitral Regurgitation
• Intervention / Treatment: Device: Carillon Mitral Contour System

Detailed Description

The EXERCISE FMR trial is a prospective, multi-center clinical trial.

The centers will utilize pre-screening of existing medical records to identify potentially eligible subjects. Once informed consent has been obtained, the subject will undergo standard of care assessments which include: Transthoracic echocardiography, transesophageal echocardiography (if necessary), and functional assessments (NYHA and KCCQ Quality of Life Questionnaire). Following final eligibility determination, eligible subjects will under the index procedure to implant the commercially available Carillon device (includes coronary sinus venogram) according to the Instructions for Use. Subject will be discharged following after standard of care discharge assessments are completed.

Implanted subjects will have follow-up assessments performed at 1 month, 6 months, and 12 months post index procedure. Most assessments performed as part of follow-up are intended to be standard of care at each institution. The only elements that may fall outside of standard of care would be the non-invasive assessments of TTE, 6-minute walk test and the questionnaire. Further, follow-up at 1 and 6 months may also not be common site practice.

• Study Type: Observational

Participation Criteria

Eligibility Criteria

• Ages Eligible for Study: 18 years and older (Adult, Older Adult)
• Accepts Healthy Volunteers: No
• Genders Eligible for Study: All

• Sampling Method: Probability Sample

Study Population

Consent up to 150 subjects suffering from heart failure and presenting with functional mitral regurgitation in order to implant 30 subjects, plus up to 3 "roll-in" subjects per site

Description

Inclusion Criteria:

• Mild-moderate-to-severe secondary MR (as assessed by qualitative, semi-quantitative and/or quantitative echocardiographic assessment (Zoghbi, JASE 2017)) in the setting of all of the following (a-d, below):

  1. Symptomatic functional (secondary mitral regurgitation defined as both: 1+ (mild) 2+ (Moderate), or 3+ (Moderate/Severe)
  2. Exacerbation of MR with exercise by at least one grade or 10 mm2 EROA
  3. Left Ventricular Ejection Fraction ≤50% by Simpson's biplane technique
  4. LVEDD >5.5 cm
• New York Heart Association (NYHA) Class II, III or ambulatory IV heart failure
• Stable heart failure medication regimen for at least 30 days prior to index procedure
• Patient deemed appropriate candidate for transcatheter mitral valve repair by the local multidisciplinary heart team
• Subject meets anatomic screening criteria as determined by angiographic screening at the time of the index procedure to ensure that implant can be sized and placed in accordance with the Instructions for Use
• Female subjects of child-bearing potential must have a negative serum βHCG test
• Age ≥ 18 years old
• The subject has read the informed consent, agrees to comply with the requirements, and has signed the informed consent to participate in the study

Exclusion Criteria:

• Hospitalization in past three (3) months due to myocardial infarction, coronary artery bypass graft surgery, and/or unstable angina
• Evidence of transient ischemic attack or stroke within three (3) months prior to intervention
• Percutaneous coronary intervention in the last 30 days
• Subjects expected to require any cardiac surgery, including surgery for coronary artery disease or for pulmonic, aortic, or tricuspid valve disease within one (1) year
• Subjects expected to require any percutaneous coronary intervention within 30 days of the index procedure.
• Pre-existing device (e.g., pacing lead) in coronary sinus (CS) / great cardiac vein (GCV), or anticipated need for cardiac resynchronization therapy (CRT) within twelve (12) months
• Presence of a coronary artery stent under the CS / GCV in the implant target zone
• Presence of left atrial appendage (LAA) clot.
• Presence of primary renal dysfunction or significantly compromised renal function as reflected by a serum creatinine > 2.2 mg/dL (194.5 μmol/L) OR estimated Glomerular Filtration Rate (eGFR) < 30 ml/min
• Poorly controlled atrial fibrillation or flutter, with poor ventricular rate control (> 100 bpm resting HR), or other poorly controlled symptomatic brady- or tachy-arrhythmias
• Uncontrolled hypertension (BP > 180 mmHg systolic and/or >105 mmHg diastolic) or hypotension (BP < 90 mmHg systolic) at baseline
• Presence of severe mitral annular calcification
• Prior mitral valve surgery
• Presence of a mechanical mitral heart valve, mitral bio-prosthetic valve or mitral annuloplasty ring
• Echocardiographic evidence of intracardiac mass, thrombus, or vegetation
• Active endocarditis
• Severe aortic stenosis (aortic valve area <1.0 cm2) or severe aortic regurgitation
• Infiltrative cardiomyopathies (e.g., amyloidosis, hemochromatosis, sarcoidosis)
• Hypertrophic cardiomyopathy, restrictive cardiomyopathy, constrictive pericarditis, or any other structural heart disease causing heart failure other than functional mitral regurgitation
• Subjects with echocardiographic documentation of non-compaction cardiomyopathy with associated hypercontractility of the cardiac structures supporting the mitral annulus
• Hemodynamic instability requiring inotropic support or mechanical heart circulatory support
• Active infections requiring current antibiotic therapy
• Severe right ventricular failure or severe tricuspid regurgitation
• History of bleeding diathesis or coagulopathy, or subject who refuses blood transfusions
• Significant organic mitral valve pathology (e.g., moderate or severe myxomatous degeneration, with or without mitral leaflet prolapse, rheumatic disease, full or partial chordal rupture)
• Allergy to contrast dye that cannot be pre-medicated
• Pregnant or planning pregnancy within next 12 months.
• Chronic severe pathology limiting survival to less than 12-months in the judgement of the investigator
• Anticipated need of left ventricular assist device within twelve (12) months
• Currently participating or has participated in another investigational study where the study primary endpoint was not reached at the time of screening
• Patient requires emergent/emergency treatment for mitral regurgitation

Study Plan

How is the study designed?

What is the study measuring?

Primary Outcome Measures

Outcome Measure	Measure Description	Time Frame
Change in MR Volume	Change in mitral regurgitant volume (mL) associated with the Carillon device from rest and exercise at 6 months post-implant, as compared to baseline	6 Months

Secondary Outcome Measures

Outcome Measure	Measure Description	Time Frame
Change of MR Severity: Quantitative MR Variables	MR severity as assessed by echocardiography in hospital, 1 month, 6 months and 12 months, in accordance with American Society of Echocardiography guidelines, compared to baseline. Quantitative MR variables to be assessed include regurgitant volume (mL), regurgitant fraction (%) and effective regurgitant orifice area (cm2, EROA) by Proximal Isovelocity Surface Area (PISA).	1, 6 & 12 Months
Change of MR severity: Semi-Quantitative Parameter (1)	Change in vena contract width. MR severity as assessed by echocardiography in hospital, 1 month, 6 months and 12 months, in accordance with American Society of Echocardiography guidelines, compared to baseline.	1, 6 & 12 Months
Change of MR severity: Semi-Quantitative Parameter (2)	Change in MV EVmax. MR severity as assessed by echocardiography in hospital, 1 month, 6 months and 12 months, in accordance with American Society of Echocardiography guidelines, compared to baseline.	1, 6 & 12 Months
Change of MR severity: Semi-Quantitative Parameter (3)	Change in pulmonary vein flow. MR severity as assessed by echocardiography in hospital, 1 month, 6 months and 12 months, in accordance with American Society of Echocardiography guidelines, compared to baseline.	1, 6 & 12 Months
Change in Left Atrial Area	Change in Left Atrial Area as assessed by echocardiography at 1, 6 and 12 months over baseline	1, 6 & 12 Months
Change in Left Atrial Diameter	Change in Left Atrial Diameter as assessed by echocardiography at 1, 6 and 12 months over baseline	1, 6 & 12 Months
Change in Left Atrial Volume Index	Change in Left Atrial Volume as assessed by echocardiography Index at 1, 6 and 12 months over baseline	1, 6 & 12 Months
Change in Left Ventricular End Systolic Volume (LVESV)	Change in Left Ventricular End Systolic Volume (LVESV) as assessed by echocardiography at 1, 6 and 12 months over baseline	1, 6 & 12 Months
Change in Pulmonary Artery Systolic Pressure	Change in Pulmonary Artery Systolic Pressure as assessed by echocardiography at 1, 6 and 12 months over baseline	1, 6 & 12 Months
Change in Quality-of-Life Overall Score	Change in Quality of Life (QoL) score, as measured by Kansas City Cardiomyopathy Questionnaire (KCCQ) at 1, 6 and 12 months over baseline	1, 6 & 12 Months
Change in NYHA	Change in New York Heart Association (NYHA) Functional Classification at 1, 6 and 12 months over baseline	1, 6 & 12 Months
Rate of Heart Failure Hospitalizations	Rate of hospitalization for heart failure at 1, 6 and 12 months	1, 6 & 12 Months
Rate of Major Cardiovascular Events	Rate of stroke, myocardial infarction, cardiovascular and all-cause mortality at 1, 6 and 12 months	1, 6 & 12 Months
Rate of Other Mitral Valve Interventions	Number of participants in need of mitral valve intervention or surgery at 1, 6 and 12 months	1, 6 & 12 Months

Collaborators and Investigators

• Sponsor: Cardiac Dimensions Pty Ltd

Study record dates

Study Major Dates

• Study Start (Anticipated): September 1, 2021
• Primary Completion (Anticipated): September 1, 2023
• Study Completion (Anticipated): September 1, 2023

Study Registration Dates

• First Submitted: May 13, 2021
• First Submitted That Met QC Criteria: September 3, 2021
• First Posted (Actual): September 10, 2021

Study Record Updates

• Last Update Posted (Actual): October 7, 2022
• Last Update Submitted That Met QC Criteria: October 5, 2022
• Last Verified: October 1, 2022

More Information

Terms related to this study

• Additional Relevant MeSH Terms: Heart Diseases; Cardiovascular Diseases; Heart Valve Diseases; Mitral Valve Insufficiency
• Other Study ID Numbers: CVP-3500-01

Plan for Individual participant data (IPD)

• Plan to Share Individual Participant Data (IPD)?: NO
• IPD Plan Description: No plans for sharing

Drug and device information, study documents

• Studies a U.S. FDA-regulated drug product: No
• Studies a U.S. FDA-regulated device product: No